Impact of the Spread of COVID-19 on Business and Operating Performance
First written in FY2020-Q1. 4 of 12 entries say "Materialised", first in FY2020-Q2. Latest entry: FY2023.
The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.
- FY2023MitigatedAnnual report
「In 2023, as social activities that had been curtailed during the COVID-19 pandemic resumed, we actively pursued marketing and sales activities, among others, to address the new business environment.」
It states that the impact of restrictions on social activities caused by the spread of COVID-19 receded and that marketing and sales activities were pursued in response to the resumption of social activities. - FY2022Ongoing impact and recovery in social activitiesAnnual report
「As social activities that had been curtailed during the COVID-19 pandemic resumed, we actively pursued marketing and sales activities, among others, to address the new business environment.」
Although the impact of COVID-19 continued, we pursued marketing and sales activities in response to the resumption of social activities and maintained our product supply system. - FY2022-Q2Ongoing impact and partial response measuresAnnual report
「Although supply chains, including international transportation, have been partially disrupted, we have responded by switching to alternative raw materials and changing transportation routes, among other measures, and the impact on our business and performance is limited.」
It also describes increased demand for Pocari Sweat and other products resulting from heightened awareness of health management while the impact of the spread of COVID-19 continued. - FY2022-Q1Ongoing impact and increased health-related demandAnnual report
「As the impact of the spread of COVID-19 continued in Japan, awareness of personal health management increased and the importance of hydration and electrolyte replenishment became more widely recognized, driving increased revenue through greater use in everyday life, including at home.」
It states that while the impact of the spread of COVID-19 continued, heightened awareness of health management led to increased demand for Pocari Sweat and other products. - FY2021Impact continues, activities recoverAnnual report
「In the second half of fiscal 2021, as the scope of social activity gradually expanded in many regions from the new-normal activity environment, the company actively pursued marketing activities adapted to the new business environment and preparations for the launch of new products.」
While the impact of the spread of COVID-19 on sales activities and consumption opportunities continued, the company advanced marketing and launch preparations in response to the expansion of social activity in the second half of the fiscal year. - FY2021-Q3Impact continues, demand recoveryAnnual report
「During the nine months ended the third quarter, the substantial revenue declines caused by the expiration of the contracts for Sprycel and Keppra were more than offset by increased revenue from the four global products Abilify Maintena, Rexulti, Evrysdi and Lonsurf, as well as the nutraceuticals-related business and other operations. Consolidated revenue increased 3.8% year on year to ¥1,107,417 million.」
While the impact of the spread of COVID-19 on outpatient numbers, consumption opportunities and sales activities continued, the company described a recovery in Pocari Sweat sales in Asia, increased demand for products such as Nature Made as health awareness rose, and a partial recovery in prescription volumes. - FY2021-Q2Impact continues, partial recoveryAnnual report
「Although the company had suspended the start-up of trial sites and patient enrollment for some development programs undergoing clinical trials, these activities have now resumed. If the suspension or delay of patient enrollment and other activities becomes more serious, the company may change its development strategy, including the progress of clinical trials and the timing of applications for marketing approval.」
While stating that the start-up of clinical trial sites and patient enrollment had resumed, the company continued to disclose the risk of an impact on trial progress and the timing of approval applications if the spread of infection worsened. It also anticipated continued effects on sales and production, including calls for people to refrain from going out, delays in raw materials and production stoppages. - FY2021-Q1MaterialisedAnnual report
「The current status of the Group in relation to the spread of COVID-19 and the management risks of concern going forward are as follows.」
The company continues to describe in specific terms the business impact and future risks of the spread of COVID-19, including fewer outpatient visits, reduced consumption opportunities due to calls for people to refrain from going out, delays in imported raw materials, temporary production-line stoppages, and suspended or delayed clinical trials. - FY2020MaterialisedAnnual report
「In the consolidated fiscal year, the Group's business activities were affected to some extent by the spread of COVID-19, but consolidated revenue increased 1.9% year on year to ¥1,422,826 million.」
While the company experienced declines in outpatients and surgeries, reduced consumption opportunities, delays in procuring raw materials, temporary production stoppages, and suspended or delayed clinical trials, revenue increased overall. - FY2020-Q3MaterialisedAnnual report
「In the third quarter, the 4 global products in the medical-related business, Abilify Maintena, Rexulti, Samsca/Jynarque and Lonsurf, grew steadily, although some products, including those outside the medical-related business, were affected by restrictions on going out and other measures associated with the spread of COVID-19.」
The impact of COVID-19 continued, with some products outside the medical-related business experiencing lower demand due to restrictions on going out, reduced activity levels and poor weather. Meanwhile, the 4 global products grew and the supply system remained stable, according to the company. - FY2020-Q2MaterialisedAnnual report
「In the second quarter, the 4 global products in the medical-related business grew steadily, although some products, including those outside the medical-related business, were affected by restrictions on going out and other measures associated with the spread of COVID-19.」
The effects of restrictions on going out, patients refraining from seeking medical care, fewer surgeries, lost consumption opportunities, delays in procuring raw materials and temporary production stoppages due to the spread of COVID-19 actually occurred. Meanwhile, the supply system remained stable and clinical trials gradually resumed. - FY2020-Q1First statedAnnual report
「At some development programs undergoing clinical trials, the company has suspended the start-up of trial sites and patient enrollment. If these conditions persist or worsen, clinical trial progress and the timing of applications for marketing approval may be delayed.」
For the first time, the company comprehensively described the impact of the spread of COVID-19 across sales, production, research and development, including declines in outpatients, restrictions on visits to medical institutions and disease-awareness activities, lost consumption opportunities, delays in procuring raw materials, temporary production stoppages, and delays in clinical trials and research activities. While describing the impact on first-quarter performance as limited, it indicated the possibility of an impact on full-year performance and the timing of approvals if the situation persisted or worsened.